FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, particularly to an antibody against LAG-3, and to a pharmaceutical composition containing such antibody. Also disclosed is an artificial genetic DNA encoding such antibody or its light or heavy chain, as well as a vector and a cell containing such DNA. Invention also relates to a method for producing an antibody against LAG-3 which provides cultivation of said host cell.
EFFECT: invention allows effectively preventing and/or treating infection or a malignant growth.
19 cl, 8 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
